Gelesis Holdings Return on Tangible Equity 2021-2022 | GLS
Current and historical return on tangible equity values for Gelesis Holdings (GLS) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Gelesis Holdings Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2022-09-30 |
$0.14B |
$-0.02B |
-148.15% |
| 2022-06-30 |
$0.10B |
$-0.01B |
-99.01% |
| 2022-03-31 |
$0.01B |
$-0.01B |
-6.15% |
| 2021-12-31 |
$-0.00B |
$-0.35B |
2.11% |
| 2021-06-30 |
$-0.16B |
$0.01B |
-4240.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.012B |
$0.011B |
|
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
|
